# **Special Issue**

# Novel Therapeutic and Preventive Approaches for Cancer

# Message from the Guest Editors

Tremendous advancements have been made to effectively combat various malignant diseases in the past few decades. Early detection and monitoring with a battery of biomarkers and targeted therapy with various molecular inhibitors are emerging continuously to increase our strength to continue our fight against cancer. On the other hand, various preventive measures such as HPV vaccination and mammographic imprinting have remarkably improved our ability to prevent or detect cancer early. Various mitochondria- and exosome-based therapeutic approaches in concert with next generation immunotherapy are also on the way to develop comprehensive measures to conquer this lethal disease. In this Special Issue, we would like to invite cutting-edge research covering the broad areas of preventive and therapeutic oncology.

#### **Guest Editors**

#### Prof. Dr. Hirendra Nath Baneriee

Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University Campus of the University of North Carolina, Elizabeth City, NC 27909, USA

#### Dr. Santanu Dasgupta

Department of Medicine, The University of Texas Health North East MD Anderson Cancer Center, 11937 US Hwy 271, Tyler, TX 75708, USA

### Deadline for manuscript submissions

closed (30 June 2019)



# **Medicines**

an Open Access Journal by MDPI

Indexed in PubMed



### mdpi.com/si/18905

Medicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
medicines@mdpi.com

mdpi.com/journal/ medicines





# **Medicines**

an Open Access Journal by MDPI

Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Medicines (ISSN 2305-6320) is an international, peer-reviewed, and open-access journal aimed at disseminating cutting-edge research in the field of drug discovery and clinical application. It publishes original research papers, research communications, letters, and systematic reviews. The contents of the papers handled are manufacture of new drugs, exploration of drug-delivery systems, therapeutic effect, action mechanism, and their modulation by intrinsic and extrinsic factors. We look forward to handling your contributions in the very near future.

### Editor-in-Chief

### Prof. Dr. Hiroshi Sakagami

Meikai University Research Institute of Odontology (M-RIO), 1-1 Keyakidai, Sakado, Saitama 350-0283, Japan

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within PubMed, PMC, CAPlus / SciFinder, and other databases.

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 45 days after submission; acceptance to publication is undertaken in 5.7 days (median values for papers published in this journal in the first half of 2025).

